Synaptogenix Inc (SNPX)

[SF Wolf]

From: Significant Cognitive Improvement with Bryostatin for Advanced Alzheimer’s Patients in the Absence of Memantine

"Results: In comparing 20 µg bryostatin with placebo for patients not taking memantine, the difference in SIB change from baseline was 6.1 points with 95% confidence interval of (1.5,10.7) and p = 0.012, suggesting 20 µg bryostatin was highly significantly better than placebo.

On the other hand, there was no treatment effect for memantine-dosed patients. Furthermore, with repeated measures of SIB over time for patients not taking memantine, the 20 µg bryostatin group showed early benefit starting at week 5 and the positive trend was sustained for the entire study follow-up. The results of these new analyses are consistent with, although clearer than, previous analyses that indicated persistence of bryostatin’s reversal of cognitive decline even 30 days after all dosing was completed."


The SIB baseline change of 6.1 points is highly significant and much better than Neurotrope and Dr. Alkon were expecting prior to the release of Phase II Top Line results (as Dr. Alkon told me in response to a question I asked of him).